BPA - HPLC/UHPLC and GC-MS Systems

The contract involves the acquisition of new High-Performance Liquid Chromatography (HPLC)/Ultra-High Performance Liquid Chromatography (UHPLC) and Gas Chromatography-Mass Spectrometry (GC-MS) systems for the Food and Drug Administration (FDA). These advanced analytical instruments are expected to significantly improve the Office of Laboratory Operations and Analytical Services (OLOAS) by increasing sample throughput through faster analysis and the ability to process multiple samples simultaneously. This enhancement will support more efficient and rapid chemical analyses, including complex multi-residue screening and targeted quantitative testing, ultimately speeding up the regulatory sample flow and reducing turnaround times for regulatory decision-making. The upgraded systems will offer improved sensitivity, selectivity, and reliability, thereby strengthening the quality and defensibility of the analytical results that underpin the FDA’s regulatory actions. The contract is structured as a base agreement with four option years, indicating a long-term partnership to support the ongoing modernization of laboratory capabilities. Contact points for the acquisition are designated, with an acquisition liaison available, though the contracting officer position is yet to be assigned. This procurement aims to equip the FDA with state-of-the-art instrumentation to enhance the effectiveness and efficiency of its laboratory operations.